R&D | May 25, 2026
AbbVie signals major oncology momentum at ASCO
With standout ADC and t-cell engager response data across hard-to-treat cancers
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
Clearance marks major shift beyond chemotherapy
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Expands Davaindia network to 2,579 stores
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The decision marks a key step in the centralized EU review process
Subscribe To Our Newsletter & Stay Updated
